Trial · NCT07900698
Clinical Impact of Ultrasound Diagnosis in Bowel Endometriosis
NCT07900698, Not yet recruiting, Erasme University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Impact of Ultrasound Diagnosis in Bowel Endometriosis. Trials, record NCT07900698. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07900698
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Impact of Ultrasound Diagnosis in Bowel Endometriosis
- NCT number
- NCT07900698
- Status
- Not yet recruiting
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Erasme University Hospital
- Conditions
- Endometriosis, Endometriosis Rectum, Endometriosis Pelvic, Endometriosis Colon
- Interventions
- preoperative transvaginal ultrasound
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Sensitivity of Transvaginal Ultrasound for Bowel Endometriosis Compared With Surgical Findings Confirmed by Histopathology | From preoperative transvaginal ultrasound to surgery and histopathology report, up to 24 months (an average of 3 months) | Percentage of patients with bowel endometriosis found at surgery (operative report) and confirmed by histopathology who were correctly identified as having bowel involvement on preoperative transvaginal ultrasound. Unit: % of patients. |
| Secondary | Percentage of Bowel Lesions With Concordant Location on Transvaginal Ultrasound and at Surgery | From preoperative transvaginal ultrasound to surgery, up to 24 months (an average of 3 months) | Percentage of surgically confirmed bowel lesions whose location on preoperative transvaginal ultrasound (rectum, rectosigmoid junction, sigmoid colon) matches the location described in the operative report. Unit: % of lesions. |
| Secondary | Correlation Between Bowel Lesion Diameter on Transvaginal Ultrasound and on Histopathology | From preoperative transvaginal ultrasound to histopathology report, up to 24 months (an average of 3 months) | Spearman's rank correlation coefficient between the largest bowel lesion diameter measured on preoperative transvaginal ultrasound (mm) and the largest lesion diameter measured on the histopathology report (mm). Unit: Spearman's rho. |
| Secondary | Percentage of Patients Undergoing Segmental Resection According to the Largest Axis of the Bowel Lesion on Transvaginal Ultrasound (< 3 cm vs ≥ 3 cm) | From preoperative transvaginal ultrasound to surgery, up to 24 months (an average of 3 months) | Percentage of patients treated by segmental bowel resection, the most radical surgical technique, versus conservative techniques (shaving or discoid excision), as recorded in the operative report, in the group with a bowel lesion largest axis \< 3 cm on preoperative transvaginal ultrasound and in the group with a largest axis ≥ 3 cm. This outcome aims to assess whether lesion size on ultrasound can predict the need for the most radical surgery. Unit: % of patients. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07900698
GET https://conductscience.org/api/trials/v1/NCT07900698/registered